Wolfgang Eiermann

PCN23: DISEASE MODELING: DEVELOPING THE INFRASTRUCTURE FOR A COMPREHENSIVE, MULTI-NATIONAL, CLINICAL AND ECONOMIC BREAST CANCER TREATMENT MODEL

Ar Bianco, R Becker, L Noe, 2001 .

Adjuvant trastuzumab in HER2-positive breast cancer.

Marc Buyse, Arlene Chan, Marek Pawlicki, 2011, The New England journal of medicine.

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Wolfgang Eiermann, Fatima Cardoso, W. Eiermann, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma

Anthony Howell, Wolfgang Eiermann, Walter Jonat, 1998, Cancer.

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

John R. Mackey, Marc Buyse, Arlene Chan, 2009 .

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

Wolfgang Eiermann, J. Robertson, A. Buzdar, 2002, Cancer.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Gideon Blumenthal, Nina Ditsch, David Cameron, 2014, The Lancet.

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

Andreas Makris, Wolfgang Eiermann, Vered Stearns, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.

Hans-Peter Sinn, Anthony Howell, Wolfgang Eiermann, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Anton Belousov, Wolfgang Eiermann, M. Cheang, 2014, Clinical Cancer Research.

Response-guided neoadjuvant chemotherapy for breast cancer.

Carsten Denkert, Andreas Schneeweiss, Stefan Paepke, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Jingqin Luo, Mitch Dowsett, Matthew J. Ellis, 2008, Journal of the National Cancer Institute.